市場調査レポート

商品コード

1401859

ファーマコゲノミクス市場の2030年までの予測：流通チャネル別、技術別、用途別、エンドユーザー別、地域別の世界分析

Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel, Technology, Application, End User and By Geography

出版日: 2023年12月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 615,569円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 778,732円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 941,895円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,112,475円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.33円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のファーマコゲノミクス市場は2023年に166億6,000万米ドルを占め、予測期間中にCAGR 11.1％で成長し、2030年には348億1,000万米ドルに達すると予測されています。

特定の薬剤に対する個人の反応に影響を与えるヒトの遺伝的変異を分析することによって薬剤を開発する研究は、ファーマコゲノミクスとして知られています。このアプローチは精密医療に不可欠であり、遺伝子マーカーに基づいて個人に合った治療計画を提供します。患者の転帰を改善し、副作用を減らし、薬効を高め、より費用対効果の高いヘルスケアを提供するために不可欠です。

米国国立がん研究所が2020年9月に発表したデータによると、2020年には米国で新たに180万6590人ががんと診断され、60万6520人ががんで死亡すると推定されています。

個別化医療の普及

個別化医療とは、個人の遺伝的、ゲノム的、臨床的特徴に合わせて医療を調整するアプローチです。医療介入をカスタマイズすることにより、治療効果を最大化し、副作用を最小化し、患者の転帰を改善することを目的としています。患者やヘルスケアプロバイダーがファーマコゲノミクスの潜在的な利点をより認識するようになるにつれ、遺伝子検査や個別化治療計画に対する需要が高まっています。さらに、製薬会社もゲノムデータに基づく標的治療に投資しています。このような患者の需要、臨床的妥当性、業界のイノベーションの融合が、ファーマコゲノミクス市場の成長を後押ししています。

コストの障壁

コストの障壁は、ファーマコゲノミクス市場に大きな抑制要因となっています。遺伝子検査とファーマコゲノミクス・サービスは高額であるため、多くの患者やヘルスケアシステムにとって利用しにくいものとなっています。DNA塩基配列決定、データ解析、解釈にかかる高額なコストは、特に資源に制約のある環境では、ファーマコゲノミクスの採用を制限する可能性があります。このような経済的負担は、個別化医療の恩恵への不平等なアクセスをもたらし、ヘルスケア格差を悪化させる。

遺伝子検査技術の進歩

遺伝子検査の進歩は、コストを下げ、アクセシビリティを高め、検査の利用可能性を拡大することによって、成長に拍車をかけることができます。遺伝学的検査は、技術の進歩に伴い、入手しやすく、安価で、より正確になってきています。さらに、ユーザーフレンドリーな家庭用検査キットやモバイルヘルスアプリケーションが開発されたことで、患者や医療専門家にとって検査プロセスが容易になった。さらに、これらの開発により、個人の遺伝情報入手が簡素化されるだけでなく、標準的な治療手順に薬理ゲノムデータを組み込むことも容易になっています。ファーマコゲノミクス市場のシェア拡大と個別化医療の広範な採用は、遺伝子検査の普及によって可能になった。

データのプライバシーとセキュリティ

遺伝子情報は非常にセンシティブであり、このデータへの誤った取り扱いや不正アクセスは、プライバシーの侵害、個人情報の盗難、差別につながる可能性があります。患者は、悪用される可能性を恐れて、遺伝子検査を受けたり、データを共有したりすることをためらうかもしれないです。さらに、遺伝子情報を保護するための規制の枠組みは絶えず進化しており、ヘルスケアプロバイダーや製薬会社にとってコンプライアンス上の課題が生じる可能性があります。したがって、市場成長の減少につながります。

COVID-19の影響

COVID-19の流行は市場に多面的な影響を与えました。一方では、遠隔医療や遠隔モニタリングを含むデジタルヘルスの普及を加速させ、データ共有や患者相談を容易にすることでファーマコゲノミクスを補完することができました。また、パンデミックの緊急性は、ヘルスケアと医薬品への研究と投資の増加につながり、ファーマコゲノミクスの進歩を促進する可能性もあった。しかし、マイナスの影響もあった。多くのヘルスケア資源と研究努力がCOVID-19に振り向けられ、ファーマコゲノミクスプロジェクトの進展が遅れる可能性があった。ファーマコゲノミクス治療の臨床試験は、ロックダウンや安全性の懸念のために遅れたり中断されたりした可能性があります。

予測期間中、DNAシーケンシングセグメントが最大となる見込み

DNAシーケンシングセグメントが最大のシェアを占めると推定されます。DNAシーケンシングは、個人のゲノムにおけるDNA塩基の正確な順序を決定することを含みます。遺伝子変異を分析することで、研究者やヘルスケアプロバイダーは、薬物反応や疾患感受性に関連する特定の遺伝子や遺伝子マーカーを特定することができます。この情報により、治療法のカスタマイズが可能になり、患者にとって最も効果的で安全な治療法の選択肢が確保されます。さらに、次世代シーケンシングなどDNAシーケンシング技術の進歩により、ゲノムデータの取得がより迅速かつコスト効率よく行えるようになったため、このセグメントの成長が促進され、ヘルスケアにおけるファーマコゲノミクスの応用可能性が拡大しています。

予測期間中にCAGRが最も高くなると予想されるのは病院・診療所セグメントです。

病院・診療所セグメントは予測期間中に有利な成長を遂げると予測されています。ヘルスケア施設は、薬物治療計画をカスタマイズするために薬理ゲノム検査を利用し、個々の患者にとって薬物が有効かつ安全であることを保証します。ファーマコゲノミクスは、臨床医が最も適した薬物療法と投与量を特定し、副作用を最小限に抑え、患者の転帰を最適化するのに役立ちます。さらに、がんから心血管疾患まで、さまざまな病状に対する治療法の選択にも役立ちます。個別化医療の需要が高まるにつれ、病院やクリニックは、ファーマコゲノミクスを日常臨床に組み込むことが不可欠となり、個別化されたデータ主導の治療計画を提供することでヘルスケアに革命をもたらしています。

最大のシェアを占める地域

推定期間中、アジア太平洋地域が最大の市場シェアを占めました。アジア太平洋地域は、ファーマコゲノミクスにとって重要かつ急速に成長している市場です。この地域は、がん、心血管疾患、糖尿病などの慢性疾患の負担増に直面しており、個別化医療とファーマコゲノミクス・ソリューションの需要が高まっています。中国、日本、韓国などのアジア太平洋地域の国々は、ゲノミクス研究に多額の投資を行っており、薬物反応や疾病に影響を与える遺伝的要因の解明が大きく進展しています。

CAGRが最も高い地域：

北米は、予測期間中に収益性の高い成長を遂げると予想されます。北米は、確立された病院、研究機関、製薬会社を含む高度なヘルスケアシステムを誇り、ファーマコゲノミクスの成長に強固な基盤を提供しています。米国のFDAなどの規制機関は、医薬品開発、承認、表示におけるファーマコゲノミクスの重要性を積極的に認識しており、このことが採用を加速しています。さらに、北米の製薬会社はファーマコゲノミクスに多額の投資を行っており、その結果、数多くの個別化治療が開発されています。この地域は、ゲノム研究、臨床試験、標的療法の開発に多額の投資を行い、ファーマコゲノミクス研究の最前線に位置しています。

無料カスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Novartis AG
Ferndale Pharma Group, Inc.
Mylan N.V.
F. Hoffmann-La Roche Ltd
Takeda Pharmaceutical Company Limited
Pfizer Inc.
AstraZeneca
Merck & Co., Inc.
Eli Lilly and Company
Sun Pharmaceutical Industries Ltd.
Lupin
NATCO Pharma Limited
Teva Pharmaceutical Industries Ltd
AbbVie Inc.
Boehringer Ingelheim International GmbH
Abbott
Bayer AG
Thermo Fisher Scientific, Inc.
Admera Health
Agilent Technologies

図表

List of Tables

Table 1 Global Pharmacogenomics Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 3 Global Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 4 Global Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 5 Global Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 6 Global Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 7 Global Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 8 Global Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 9 Global Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 10 Global Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 11 Global Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 12 Global Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 13 Global Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 14 Global Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 15 Global Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 16 Global Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 17 Global Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 18 Global Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 19 Global Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 20 Global Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 21 Global Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 22 Global Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 23 Global Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 24 Global Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 25 North America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
Table 26 North America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 27 North America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 28 North America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 29 North America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 30 North America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 31 North America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 32 North America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 33 North America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 34 North America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 35 North America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 36 North America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 37 North America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 38 North America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 39 North America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 40 North America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 41 North America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 42 North America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 43 North America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 44 North America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 45 North America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 46 North America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 47 North America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 48 North America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 49 Europe Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
Table 50 Europe Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 51 Europe Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 52 Europe Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 53 Europe Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 54 Europe Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 55 Europe Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 56 Europe Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 57 Europe Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 58 Europe Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 59 Europe Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 60 Europe Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 61 Europe Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 62 Europe Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 63 Europe Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 64 Europe Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 65 Europe Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 66 Europe Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 67 Europe Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 68 Europe Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 69 Europe Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 70 Europe Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 71 Europe Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 72 Europe Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 73 Asia Pacific Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
Table 74 Asia Pacific Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 75 Asia Pacific Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 76 Asia Pacific Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 77 Asia Pacific Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 78 Asia Pacific Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 79 Asia Pacific Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 80 Asia Pacific Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 81 Asia Pacific Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 82 Asia Pacific Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 83 Asia Pacific Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 84 Asia Pacific Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 85 Asia Pacific Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 86 Asia Pacific Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 87 Asia Pacific Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 88 Asia Pacific Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 89 Asia Pacific Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 90 Asia Pacific Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 91 Asia Pacific Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 92 Asia Pacific Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 93 Asia Pacific Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 94 Asia Pacific Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 95 Asia Pacific Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 96 Asia Pacific Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 97 South America Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
Table 98 South America Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 99 South America Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 100 South America Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 101 South America Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 102 South America Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 103 South America Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 104 South America Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 105 South America Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 106 South America Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 107 South America Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 108 South America Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 109 South America Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 110 South America Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 111 South America Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 112 South America Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 113 South America Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 114 South America Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 115 South America Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 116 South America Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 117 South America Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 118 South America Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 119 South America Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 120 South America Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)
Table 121 Middle East & Africa Pharmacogenomics Market Outlook, By Country (2021-2030) ($MN)
Table 122 Middle East & Africa Pharmacogenomics Market Outlook, By Distribution Channel (2021-2030) ($MN)
Table 123 Middle East & Africa Pharmacogenomics Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
Table 124 Middle East & Africa Pharmacogenomics Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
Table 125 Middle East & Africa Pharmacogenomics Market Outlook, By Online Pharmacy (2021-2030) ($MN)
Table 126 Middle East & Africa Pharmacogenomics Market Outlook, By Technology (2021-2030) ($MN)
Table 127 Middle East & Africa Pharmacogenomics Market Outlook, By DNA Sequencing (2021-2030) ($MN)
Table 128 Middle East & Africa Pharmacogenomics Market Outlook, By Polymerase Chain Reaction (2021-2030) ($MN)
Table 129 Middle East & Africa Pharmacogenomics Market Outlook, By Microarray (2021-2030) ($MN)
Table 130 Middle East & Africa Pharmacogenomics Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
Table 131 Middle East & Africa Pharmacogenomics Market Outlook, By Electrophoresis (2021-2030) ($MN)
Table 132 Middle East & Africa Pharmacogenomics Market Outlook, By Application (2021-2030) ($MN)
Table 133 Middle East & Africa Pharmacogenomics Market Outlook, By Drug Discovery (2021-2030) ($MN)
Table 134 Middle East & Africa Pharmacogenomics Market Outlook, By Oncology (2021-2030) ($MN)
Table 135 Middle East & Africa Pharmacogenomics Market Outlook, By Neurology (2021-2030) ($MN)
Table 136 Middle East & Africa Pharmacogenomics Market Outlook, By Pain Management (2021-2030) ($MN)
Table 137 Middle East & Africa Pharmacogenomics Market Outlook, By Cardiovascular diseases (2021-2030) ($MN)
Table 138 Middle East & Africa Pharmacogenomics Market Outlook, By Psychiatry (2021-2030) ($MN)
Table 139 Middle East & Africa Pharmacogenomics Market Outlook, By Infectious diseases (2021-2030) ($MN)
Table 140 Middle East & Africa Pharmacogenomics Market Outlook, By Other Applications (2021-2030) ($MN)
Table 141 Middle East & Africa Pharmacogenomics Market Outlook, By End User (2021-2030) ($MN)
Table 142 Middle East & Africa Pharmacogenomics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
Table 143 Middle East & Africa Pharmacogenomics Market Outlook, By Research Institutions and Academic Institutes (2021-2030) ($MN)
Table 144 Middle East & Africa Pharmacogenomics Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24379

According to Stratistics MRC, the Global Pharmacogenomics Market is accounted for $16.66 billion in 2023 and is expected to reach $34.81 billion by 2030 growing at a CAGR of 11.1% during the forecast period. The study of developing drugs by analysing genetic variations in humans that affect an individual's response to a particular drug is known as pharmacogenomics. This approach is vital for precision medicine, offering personalised treatment plans based on genetic markers. It is essential to improving patient outcomes, reducing adverse drug reactions, enhancing medication efficacy, and providing more cost-effective healthcare.

According to data published by National Cancer Institute in September 2020, stated that an estimated 1,806,590 new cases of cancer will be diagnosed in the U.S. and 606,520 people will die from the disease in 2020.

Market Dynamics:

Driver:

Increasing adoption of personalized medicine

Personalised medicine is an approach that tailors medical treatments to an individual's genetic, genomic, and clinical characteristics. It aims to maximise treatment effectiveness, minimise side effects, and improve patient outcomes by customising healthcare interventions. As patients and healthcare providers become more aware of the potential benefits of pharmacogenomics, the demand for genetic testing and personalised treatment plans is on the rise. Furthermore, pharmaceutical companies are also investing in targeted therapies based on genomic data. This convergence of patient demand, clinical relevance, and industry innovation is propelling the growth of the pharmacogenomics market.

Restraint:

Cost barriers

Cost barriers pose a significant restraint on the Pharmacogenomics market. Genetic testing and pharmacogenomic services can be expensive, making them inaccessible to many patients and healthcare systems. The high costs of DNA sequencing, data analysis, and interpretation can limit the adoption of pharmacogenomics, especially in resource-constrained environments. This financial burden can result in unequal access to the benefits of personalised medicine, exacerbating healthcare disparities.

Opportunity:

Advancements in genetic testing technologies

Developments in genetic testing can spur growth by lowering the cost, increasing accessibility, and expanding the availability of testing. Genetic testing is getting easier to obtain, less expensive, and more accurate as technology advances. Furthermore, the process is made easier for patients and healthcare professionals by the creation of user-friendly at-home testing kits and mobile health applications. Moreover, these developments not only simplify genetic information availability for individuals but also make it easier to incorporate pharmacogenomic data into standard therapeutic procedures. Growing pharmacogenomics market share and wider adoption of personalised medicine are made possible by the increasing prevalence of genetic testing.

Threat:

Data privacy and security

Genetic information is highly sensitive, and the mishandling or unauthorised access to this data could lead to privacy breaches, identity theft, or discrimination. Patients may be hesitant to undergo genetic testing or share their data, fearing potential misuse. Furthermore, regulatory frameworks for safeguarding genetic information are continually evolving and can create compliance challenges for healthcare providers and pharmaceutical companies. Hence, it will lead to a decrease in market growth.

COVID-19 Impact

The COVID-19 pandemic has had a multifaceted impact on the market. On one hand, it accelerated the adoption of digital health, including telehealth and remote monitoring, which can complement pharmacogenomics by facilitating data sharing and patient consultations. The urgency of the pandemic also led to increased research and investment in healthcare and pharmaceuticals, potentially driving advancements in pharmacogenomics. However, there were negative effects as well. Many healthcare resources and research efforts were redirected toward COVID-19, potentially slowing the progress of pharmacogenomics projects. Clinical trials for pharmacogenomic therapies may have been delayed or disrupted due to lockdowns and safety concerns.

The DNA Sequencing segment is expected to be the largest during the forecast period

The DNA Sequencing segment is estimated to hold the largest share. DNA sequencing involves determining the precise order of DNA bases in an individual's genome. By analysing genetic variations, researchers and healthcare providers can identify specific genes and genetic markers relevant to drug response and disease susceptibility. This information enables the customization of medical treatments, ensuring the most effective and safe therapeutic options for patients. In addition, advances in DNA sequencing technologies, such as next-generation sequencing, have made it faster and more cost-effective to obtain genomic data, driving the growth of this segment and expanding the potential applications of pharmacogenomics in healthcare.

The Hospitals & Clinics segment is expected to have the highest CAGR during the forecast period

The Hospitals & Clinics segment is anticipated to have lucrative growth during the forecast period. The healthcare facilities utilise pharmacogenomic testing to customise drug treatment plans, ensuring that medications are both effective and safe for individual patients. Pharmacogenomics can help clinicians identify the most suitable drug therapies and dosages, minimising adverse reactions and optimising patient outcomes. Furthermore, it aids in the selection of treatments for various medical conditions, from cancer to cardiovascular diseases. As the demand for personalised medicine grows, hospitals and clinics are essential in integrating pharmacogenomics into routine clinical practice, revolutionising healthcare by providing individualised, data-driven treatment plans.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. The Asia-Pacific region is a significant and rapidly growing market for pharmacogenomics. The region faces a rising burden of chronic diseases, including cancer, cardiovascular diseases, and diabetes, which has led to a growing demand for personalised medicine and pharmacogenomic solutions. Countries in the Asia-Pacific region, such as China, Japan, and South Korea, have made substantial investments in genomics research, leading to significant advancements in understanding genetic factors influencing drug responses and diseases.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America boasts advanced healthcare systems, including well-established hospitals, research institutions, and pharmaceutical companies, providing a solid foundation for the growth of pharmacogenomics. Regulatory agencies, such as the FDA in the United States, have been proactive in recognising the importance of pharmacogenomics in drug development, approval, and labelling, which accelerates its adoption. Furthermore, North American pharmaceutical companies have heavily invested in pharmacogenomics, resulting in the development of numerous personalised therapies. The region is at the forefront of pharmacogenomic research, with substantial investments in genomic studies, clinical trials, and the development of targeted therapies.

Key players in the market:

Some of the key players in the Pharmacogenomics Market include Novartis AG, Ferndale Pharma Group, Inc., Mylan N.V., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc., AstraZeneca, Merck & Co., Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Lupin, NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boehringer Ingelheim International GmbH, Abbott, Bayer AG, Thermo Fisher Scientific, Inc., Admera Health and Agilent Technologies.

Key Developments:

In October 2023, Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the inflammation of HS.2

In October 2023, Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

Distribution Channels Covered:

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Technologies Covered:

DNA Sequencing
Polymerase Chain Reaction
Microarray
Mass Spectrometry
Electrophoresis

Applications Covered:

Drug Discovery
Oncology
Neurology
Pain Management
Cardiovascular diseases
Psychiatry
Infectious diseases
Other Applications

End Users Covered:

Hospitals & Clinics
Research Institutions and Academic Institutes
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Pharmacogenomics Market, By Distribution Channel

5.1 Introduction
5.2 Hospital Pharmacy
5.3 Retail Pharmacy
5.4 Online Pharmacy

6 Global Pharmacogenomics Market, By Technology

6.1 Introduction
6.2 DNA Sequencing
6.3 Polymerase Chain Reaction
6.4 Microarray
6.5 Mass Spectrometry
6.6 Electrophoresis

7 Global Pharmacogenomics Market, By Application

7.1 Introduction
7.2 Drug Discovery
7.3 Oncology
7.4 Neurology
7.5 Pain Management
7.6 Cardiovascular diseases
7.7 Psychiatry
7.8 Infectious diseases
7.9 Other Applications

8 Global Pharmacogenomics Market, By End User

8.1 Introduction
8.2 Hospitals & Clinics
8.3 Research Institutions and Academic Institutes
8.4 Other End Users

9 Global Pharmacogenomics Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Novartis AG
11.2 Ferndale Pharma Group, Inc.
11.3 Mylan N.V.
11.4 F. Hoffmann-La Roche Ltd
11.5 Takeda Pharmaceutical Company Limited
11.6 Pfizer Inc.
11.7 AstraZeneca
11.8 Merck & Co., Inc.
11.9 Eli Lilly and Company
11.10 Sun Pharmaceutical Industries Ltd.
11.11 Lupin
11.12 NATCO Pharma Limited
11.13 Teva Pharmaceutical Industries Ltd
11.14 AbbVie Inc.
11.15 Boehringer Ingelheim International GmbH
11.16 Abbott
11.17 Bayer AG
11.18 Thermo Fisher Scientific, Inc.
11.19 Admera Health
11.20 Agilent Technologies

ファーマコゲノミクス市場の2030年までの予測： 流通チャネル別、技術別、用途別、エンドユーザー別、地域別の世界分析

Pharmacogenomics Market Forecasts to 2030 - Global Analysis By Distribution Channel, Technology, Application, End User and By Geography

COVID-19の影響

最大のシェアを占める地域

CAGRが最も高い地域：

無料カスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のファーマコゲノミクス市場：流通チャネル別

第6章 世界のファーマコゲノミクス市場：技術別

第7章 世界のファーマコゲノミクス市場：用途別

第8章 世界のファーマコゲノミクス市場：エンドユーザー別

第9章 世界のファーマコゲノミクス市場：地域別

第10章 主な発展

第11章 企業プロファイル